{"transactions":[{"id":1147003,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":79741,"kind":"person","name":"Thomas Dolca","position":1,"cik":"0001768239","reported_name":"Thomas Dolca","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-05-15T16:06:14.000Z","date":"2025-05-15","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":41000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was cancelled without consideration pursuant to the terms of that certain Agreement and Plan of Merger, dated April 1, 2025, by and among the Issuer, Concentra Biosciences, LLC and Concentra Merger Sub III, Inc."}],"balance_after":0,"derivative":{"exercise_price":1.42,"expiration_date":"2034-05-24","underlying":"Common Stock","underlying_shares":41000},"source":{"system":"sec-edgar","filing":"0001104659-25-049419","document":"tm2514731-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1564824/000110465925049419/tm2514731-7_4seq1.xml","form_type":"4"}},{"id":1147002,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":79741,"kind":"person","name":"Thomas Dolca","position":1,"cik":"0001768239","reported_name":"Thomas Dolca","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-05-15T16:06:14.000Z","date":"2025-05-15","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":154786,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was cancelled without consideration pursuant to the terms of that certain Agreement and Plan of Merger, dated April 1, 2025, by and among the Issuer, Concentra Biosciences, LLC and Concentra Merger Sub III, Inc."}],"balance_after":0,"derivative":{"exercise_price":5.55,"expiration_date":"2033-08-01","underlying":"Common Stock","underlying_shares":154786},"source":{"system":"sec-edgar","filing":"0001104659-25-049419","document":"tm2514731-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1564824/000110465925049419/tm2514731-7_4seq1.xml","form_type":"4"}},{"id":1498823,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":79741,"kind":"person","name":"Thomas Dolca","position":1,"cik":"0001768239","reported_name":"Thomas Dolca","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-29T16:05:03.000Z","date":"2024-05-24","kind":"grant","planned":false,"acquired":true,"shares":41000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 100% of the shares on the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the Issuer's next Annual Meeting of stockholders that occurs following the grant, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":41000,"derivative":{"exercise_price":1.42,"expiration_date":"2034-05-24","underlying":"Common Stock","underlying_shares":41000},"source":{"system":"sec-edgar","filing":"0000950170-24-065906","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1564824/000095017024065906/ownership.xml","form_type":"4"}},{"id":1809832,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":79741,"kind":"person","name":"Thomas Dolca","position":1,"cik":"0001768239","reported_name":"Thomas Dolca","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-11T16:11:53.000Z","date":"2023-08-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":13300,"price":26.12,"value":347396.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This stock option award, which vested in full upon the earlier of the one year anniversary of the grant date or the date of the Issuer's next annual stockholders' meeting, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":13.88,"expiration_date":"2032-05-25","underlying":"Common Stock","underlying_shares":13300},"source":{"system":"sec-edgar","filing":"0001209191-23-045430","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919123045430/doc4.xml","form_type":"4"}},{"id":1809831,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":79741,"kind":"person","name":"Thomas Dolca","position":1,"cik":"0001768239","reported_name":"Thomas Dolca","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-11T16:11:53.000Z","date":"2023-08-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5948,"price":23.19,"value":137934.12,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This stock option award, which vested in full upon the earlier of the one year anniversary of the grant date or the date of the Issuer's next annual stockholders' meeting, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":16.81,"expiration_date":"2031-06-03","underlying":"Common Stock","underlying_shares":5948},"source":{"system":"sec-edgar","filing":"0001209191-23-045430","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919123045430/doc4.xml","form_type":"4"}},{"id":1809830,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":79741,"kind":"person","name":"Thomas Dolca","position":1,"cik":"0001768239","reported_name":"Thomas Dolca","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-11T16:11:53.000Z","date":"2023-08-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":23522,"price":25.23,"value":593460.06,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award, which provided for ratable vesting in 36 monthly installments beginning on November 6, 2020, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":14.77,"expiration_date":"2030-10-05","underlying":"Common Stock","underlying_shares":23522},"source":{"system":"sec-edgar","filing":"0001209191-23-045430","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919123045430/doc4.xml","form_type":"4"}},{"id":1809829,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":79741,"kind":"person","name":"Thomas Dolca","position":1,"cik":"0001768239","reported_name":"Thomas Dolca","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-11T16:11:53.000Z","date":"2023-08-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":13300,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below).  Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received:  (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a \"CVR\"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the \"Contingent Value Rights Agreement\") entered into concurrent with completion of the Merger."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-045430","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919123045430/doc4.xml","form_type":"4"}},{"id":1815903,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":79741,"kind":"person","name":"Thomas Dolca","position":1,"cik":"0001768239","reported_name":"Thomas Dolca","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2023-08-03T18:03:35.000Z","date":"2023-08-01","kind":"grant","planned":false,"acquired":true,"shares":154786,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to one thirty-sixth (1/36) of the shares monthly over a three year period, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":154786,"derivative":{"exercise_price":5.55,"expiration_date":"2033-08-01","underlying":"Common Stock","underlying_shares":154786},"source":{"system":"sec-edgar","filing":"0001209191-23-044535","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1564824/000120919123044535/doc4.xml","form_type":"4"}},{"id":1873253,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":79741,"kind":"person","name":"Thomas Dolca","position":1,"cik":"0001768239","reported_name":"Thomas Dolca","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-05-31T19:21:30.000Z","date":"2023-05-26","kind":"exercise","planned":false,"acquired":false,"shares":3300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one share of Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"100% of the RSUs vested on May 26, 2023, subject to the Reporting Persons continued service to the Issuer on the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"100% of the RSUs vested on May 26, 2023, subject to the Reporting Persons continued service to the Issuer on the vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3300},"source":{"system":"sec-edgar","filing":"0001209191-23-033186","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919123033186/doc4.xml","form_type":"4"}},{"id":1873252,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":79741,"kind":"person","name":"Thomas Dolca","position":1,"cik":"0001768239","reported_name":"Thomas Dolca","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-31T19:21:30.000Z","date":"2023-05-26","kind":"exercise","planned":false,"acquired":true,"shares":3300,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis."}],"balance_after":13300,"source":{"system":"sec-edgar","filing":"0001209191-23-033186","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919123033186/doc4.xml","form_type":"4"}},{"id":2165467,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":79741,"kind":"person","name":"Thomas Dolca","position":1,"cik":"0001768239","reported_name":"Thomas Dolca","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-06T16:35:48.000Z","date":"2022-09-02","kind":"purchase","acquired":true,"shares":300,"price":21.2,"value":6360.0,"ownership":{"direct":true},"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001209191-22-048759","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919122048759/doc4.xml","form_type":"4"}},{"id":2165466,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":79741,"kind":"person","name":"Thomas Dolca","position":1,"cik":"0001768239","reported_name":"Thomas Dolca","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-06T16:35:48.000Z","date":"2022-09-02","kind":"purchase","acquired":true,"shares":9700,"price":21.22,"value":205834.0,"ownership":{"direct":true},"balance_after":9700,"source":{"system":"sec-edgar","filing":"0001209191-22-048759","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919122048759/doc4.xml","form_type":"4"}},{"id":2251264,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":79741,"kind":"person","name":"Thomas Dolca","position":1,"cik":"0001768239","reported_name":"Thomas Dolca","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2022-05-31T18:25:28.000Z","date":"2022-05-26","kind":"grant","acquired":true,"shares":3300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"100% of the RSUs will vest on May 26, 2023, subject to the Reporting Person's continued service to the Issuer on the vesting date."}],"balance_after":3300,"derivative":{"expiration_date":"2023-05-26","underlying":"Common Stock","underlying_shares":3300},"source":{"system":"sec-edgar","filing":"0001209191-22-032960","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919122032960/doc4.xml","form_type":"4"}},{"id":2251263,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":79741,"kind":"person","name":"Thomas Dolca","position":1,"cik":"0001768239","reported_name":"Thomas Dolca","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-31T18:25:28.000Z","date":"2022-05-26","kind":"grant","acquired":true,"shares":13300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the stock option will vest on May 26, 2023, subject to the Reporting Person's continued service to the Issuer on the vesting date."}],"balance_after":13300,"derivative":{"exercise_price":13.88,"expiration_date":"2032-05-25","underlying":"Common Stock","underlying_shares":13300},"source":{"system":"sec-edgar","filing":"0001209191-22-032960","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919122032960/doc4.xml","form_type":"4"}},{"id":2679180,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":79741,"kind":"person","name":"Thomas Dolca","position":1,"cik":"0001768239","reported_name":"Thomas Dolca","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-07T21:38:15.000Z","date":"2021-06-04","kind":"grant","acquired":true,"shares":5948,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award will fully vest upon the earlier of 1) the Issuer's next annual stockholder meeting, or 2) June 4, 2022, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":5948,"derivative":{"exercise_price":16.81,"expiration_date":"2031-06-03","underlying":"Common Stock","underlying_shares":5948},"source":{"system":"sec-edgar","filing":"0001209191-21-038800","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919121038800/doc4.xml","form_type":"4"}},{"id":2907879,"issuer":{"id":6560,"kind":"organization","name":"Equillium, Inc."},"owners":[{"id":79741,"kind":"person","name":"Thomas Dolca","position":1,"cik":"0001768239","reported_name":"Thomas Dolca","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-01-13T21:20:39.000Z","date":"2021-01-11","kind":"grant","acquired":true,"shares":450000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years."}],"balance_after":450000,"derivative":{"exercise_price":5.2,"expiration_date":"2031-01-10","underlying":"Common Stock","underlying_shares":450000},"source":{"system":"sec-edgar","filing":"0001209191-21-003422","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746466/000120919121003422/doc4.xml","form_type":"4"}},{"id":3010809,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":79741,"kind":"person","name":"Thomas Dolca","position":1,"cik":"0001768239","reported_name":"Thomas Dolca","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-10-07T21:06:11.000Z","date":"2020-10-06","kind":"grant","acquired":true,"shares":23522,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as of 1/36 of the total shares monthly beginning on November 6, 2020 until fully vested, subject to the Reporting\nPerson's provision of service to the Issuer on each vesting date."}],"balance_after":23522,"derivative":{"exercise_price":14.77,"expiration_date":"2030-10-05","underlying":"Common Stock","underlying_shares":23522},"source":{"system":"sec-edgar","filing":"0001209191-20-054250","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919120054250/doc4.xml","form_type":"4"}},{"id":3021544,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":79741,"kind":"person","name":"Thomas Dolca","position":1,"cik":"0001768239","reported_name":"Thomas Dolca","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-09-28T17:16:30.000Z","date":"2020-09-28","kind":"disposition_to_issuer","acquired":false,"shares":55000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."}],"balance_after":0,"derivative":{"exercise_price":67.31,"expiration_date":"2030-03-04","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001209191-20-052226","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1510487/000120919120052226/doc4.xml","form_type":"4"}},{"id":3021543,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":79741,"kind":"person","name":"Thomas Dolca","position":1,"cik":"0001768239","reported_name":"Thomas Dolca","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-09-28T17:16:30.000Z","date":"2020-09-28","kind":"disposition_to_issuer","acquired":false,"shares":60000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."}],"balance_after":0,"derivative":{"exercise_price":35.42,"expiration_date":"2029-02-28","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001209191-20-052226","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1510487/000120919120052226/doc4.xml","form_type":"4"}},{"id":3021542,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":79741,"kind":"person","name":"Thomas Dolca","position":1,"cik":"0001768239","reported_name":"Thomas Dolca","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-09-28T17:16:30.000Z","date":"2020-09-28","kind":"disposition_to_issuer","acquired":false,"shares":168057,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."}],"balance_after":0,"derivative":{"exercise_price":23.77,"expiration_date":"2028-10-22","underlying":"Common Stock","underlying_shares":168057},"source":{"system":"sec-edgar","filing":"0001209191-20-052226","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1510487/000120919120052226/doc4.xml","form_type":"4"}},{"id":3021541,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":79741,"kind":"person","name":"Thomas Dolca","position":1,"cik":"0001768239","reported_name":"Thomas Dolca","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-09-28T17:16:30.000Z","date":"2020-09-28","kind":"other","acquired":false,"shares":2207,"price":100,"value":220700.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the \"Issuer\"), Sanofi (\"Sanofi\") and Kortex Acquisition Corp. (\"Purchaser\") (the \"Merger Agreement\"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), these shares were canceled in exchange for $100.00 per share in cash, without interest and subject to any applicable withholding taxes."},{"field":"shares","element":"transactionShares","label":"F2","text":"Includes 381 shares acquired under the Employment Stock Purchase Plan on September 25, 2020."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-20-052226","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1510487/000120919120052226/doc4.xml","form_type":"4"}},{"id":3050742,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":79741,"kind":"person","name":"Thomas Dolca","position":1,"cik":"0001768239","reported_name":"Thomas Dolca","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-08-20T20:17:21.000Z","date":"2020-08-18","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vested and became exercisable as to 25% of the shares subject to the option on October 22, 2019, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date."}],"balance_after":168057,"derivative":{"exercise_price":23.77,"expiration_date":"2028-10-22","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-20-047842","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1510487/000120919120047842/doc4.xml","form_type":"4"}},{"id":3050741,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":79741,"kind":"person","name":"Thomas Dolca","position":1,"cik":"0001768239","reported_name":"Thomas Dolca","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-08-20T20:17:21.000Z","date":"2020-08-18","kind":"sale","acquired":false,"shares":15000,"price":100,"value":1500000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":1826,"source":{"system":"sec-edgar","filing":"0001209191-20-047842","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1510487/000120919120047842/doc4.xml","form_type":"4"}},{"id":3050740,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":79741,"kind":"person","name":"Thomas Dolca","position":1,"cik":"0001768239","reported_name":"Thomas Dolca","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-08-20T20:17:21.000Z","date":"2020-08-18","kind":"exercise","acquired":true,"shares":15000,"price":23.77,"value":356550.0,"ownership":{"direct":true},"balance_after":16826,"source":{"system":"sec-edgar","filing":"0001209191-20-047842","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1510487/000120919120047842/doc4.xml","form_type":"4"}},{"id":3080153,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":79741,"kind":"person","name":"Thomas Dolca","position":1,"cik":"0001768239","reported_name":"Thomas Dolca","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-07-17T20:01:31.000Z","date":"2020-07-15","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option vested and became exercisable as to 25% of the shares subject to the option on October 22, 2019, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date."}],"balance_after":183057,"derivative":{"exercise_price":23.77,"expiration_date":"2028-10-22","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-20-043008","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1510487/000120919120043008/doc4.xml","form_type":"4"}},{"id":3080152,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":79741,"kind":"person","name":"Thomas Dolca","position":1,"cik":"0001768239","reported_name":"Thomas Dolca","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-07-17T20:01:31.000Z","date":"2020-07-15","kind":"sale","acquired":false,"shares":15000,"price":80.0713,"value":1201069.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $80.00 to $80.28 per share. Upon request by the Commission staff, Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."}],"balance_after":1826,"source":{"system":"sec-edgar","filing":"0001209191-20-043008","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1510487/000120919120043008/doc4.xml","form_type":"4"}},{"id":3080151,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":79741,"kind":"person","name":"Thomas Dolca","position":1,"cik":"0001768239","reported_name":"Thomas Dolca","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-07-17T20:01:31.000Z","date":"2020-07-15","kind":"exercise","acquired":true,"shares":15000,"price":23.77,"value":356550.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 1,332 shares shares acquired under the Employment Stock Purchase Plan on May 15, 2020."}],"balance_after":16826,"source":{"system":"sec-edgar","filing":"0001209191-20-043008","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1510487/000120919120043008/doc4.xml","form_type":"4"}},{"id":3224207,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":79741,"kind":"person","name":"Thomas Dolca","position":1,"cik":"0001768239","reported_name":"Thomas Dolca","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-03-05T17:28:50.000Z","date":"2020-03-05","kind":"grant","acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable as to 25% of the shares subject to the option on March 5, 2021, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date."}],"balance_after":55000,"derivative":{"exercise_price":67.31,"expiration_date":"2030-03-04","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001209191-20-016693","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1510487/000120919120016693/doc4.xml","form_type":"4"}},{"id":3333637,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":79741,"kind":"person","name":"Thomas Dolca","position":1,"cik":"0001768239","reported_name":"Thomas Dolca","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2019-12-20T21:00:50.000Z","date":"2019-12-19","kind":"sale","acquired":false,"shares":495,"price":60,"value":29700.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 493 shares and 496 shares acquired under the Employment Stock Purchase Plan on May 15, 2019 and November 15, 2019 respectively."}],"balance_after":494,"source":{"system":"sec-edgar","filing":"0001209191-19-061667","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1510487/000120919119061667/doc4.xml","form_type":"4"}},{"id":3603756,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":79741,"kind":"person","name":"Thomas Dolca","position":1,"cik":"0001768239","reported_name":"Thomas Dolca","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-03-08T17:40:16.000Z","date":"2019-03-01","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable as to 25% of the shares subject to the option on March 1, 2020, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date."}],"balance_after":60000,"derivative":{"exercise_price":35.42,"expiration_date":"2029-02-28","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001209191-19-018226","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1510487/000120919119018226/doc4.xml","form_type":"4"}}]}